(+86)18613012387
info@royallee.cn
EN
CN
TH
IDN 
ARFirst, the patient's blood is drawn and processed in the laboratory to isolate autologous platelet-rich plasma (PRP). Platelets are subjected to rapid freezing to form ice crystals, which pierce the cell membrane like needles. Subsequently, high-speed centrifugation is used to squeeze the platelets, releasing substances such as clotting factors and growth factors. Therapeutic drug solution is then added, and under the action of a high-frequency ultrasonic field, the drugs are loaded into the platelet membrane to obtain drug-loaded autologous PRP, which is finally administered to the lesion site.
Chemotherapy is one of the cornerstones of anti-cancer treatment. However, low efficacy and drug resistance of chemotherapeutic drugs are common causes of anti-cancer treatment failure. Ordinary chemotherapeutic drugs generally act in the body for less than 48 hours. In contrast, platelets have a natural targeting affinity for tumor cells, a survival time of 7-14 days, and a drug release duration that is 3-7 times longer than that of ordinary chemotherapy. The autologous platelet nano-targeted drug delivery system has no allogeneic antigens and will not be actively cleared by the body, enabling sustained and slow release of anti-cancer drugs, reversing drug resistance to chemotherapeutic agents, and enhancing the anti-tumor therapeutic effect.
Therapeutic Advantages
Using autologous platelets as nano-carriers for anti-tumor drugs is suitable for nano-targeted synergistic treatment of anti-tumor drugs. It can enhance efficacy, overcome drug resistance, increase intracellular drug concentration in tumor cells, and prolong the action time of anti-tumor drugs. It still achieves favorable therapeutic effects in patients with poor response to traditional treatments or drug resistance to chemotherapy or targeted therapy.
Autologous platelet drug-loaded precise tumor therapy is safe and effective, significantly reducing the side effects of cancer chemotherapy. It avoids hair loss, nausea, vomiting, and does not damage normal tissues and organs.
Indications
Autologous platelets used as nano-carriers for anti-tumor drugs are suitable for patients with positive immunohistochemical CD44 and P-selectin receptors.
Patients with various tumors who are eligible for corresponding intravenous chemotherapy, arterial interventional therapy, thoracic and abdominal perfusion therapy, intrathecal injection therapy (using chemotherapeutic drugs), injectable targeted therapy drugs, or injectable immunotherapy drugs may consider autologous platelet drug loading to improve treatment outcomes.
Examples include: brain cancer, rectal cancer, esophageal cancer, breast cancer, pancreatic cancer, prostate cancer, bone metastasis, spinal cord tumors, etc.
Customer satisfaction